PEPG
PepGen Inc.
Healthcare — Biotechnology
PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1. It is also involved in FREEDOM-OLE, an open label expansion study. The company was founded in 2018 and is based in Boston, Massachusetts.
None
8 analysts
$2.21
$-0.21 (-8.68%)
Target:
$10.25
(363.8%)
Price History
52-Week Range
Sign in to add PEPG to a watchlist or set price alerts.
Fundamentals
| Market Cap | $125.20M |
| P/E Ratio (TTM) | - |
| Forward P/E | -1.47 |
| EPS (TTM) | $-1.46 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | -68.40% |
| Debt/Equity | 12.36 |
| Recommendation | None |
| Analyst Target | $10.25 |
| Analysts | 8 |
| Next Earnings | Aug 6, 2026 BMO |
| Indexes | - |
Technical Indicators
| RSI (14) | 77.9 |
| Beta | 1.93 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $7.80 |
| 52-Week Low | $1.01 |
| 50-Day Avg | $1.61 |
| 200-Day Avg | $4.07 |
| Avg Volume | 967.1K |
| Volume | 682.5K |
Performance Analysis
NEUTRALPEPG presents a mixed picture with both positive and negative indicators.
~
Trading at 18% of its 52-week range.
-
RSI at 77.9 indicates overbought conditions — a pullback may be due.
~
Wall Street consensus is "none" from 8 analysts.
+
Average analyst target of $10.25 implies 363.8% upside.
Recent News
Loading news...
Last updated: Jul 02, 2026 13:26 UTC
Back to Screener Export Report